UC San Diego Cancer Researchers Identify Novel Drug Target For Multiple Tumor Types
--Sharing is Caring--

Novel Drug Target For Multiple Tumor Types By UC San Diego Researchers

A group of Scientists has identified an enzyme which plays a key role in remodeling the plasma membrane of multiple cancer cell types that are required for both survivals of tumors and also their uncontrolled enlargement. The study was led by chief researchers at University of California San Diego School of Medicine and the Ludwig Institute for Cancer Research at UC San Diego. The study was published in Cell Metabolism and suggests a possible target for new drugs.

“Cancers are distinguished not only by significant changes in their genomes but also by profound shifts in how they consume and use nutrition to propel rapid tumor development,” said senior author Paul S. Mischel. How can these varied aspects fit together and will they be cared for, for the benefit of patients”

In the new study, conducted in collaboration with Benjamin Cravatt, PhD, professor at Scripps Research, and led by original author Junfeng Bi, PhD, in Mischel’s lab, researchers identified a molecule called LPCAT1, whose degrees increase in cancer and which plays a key role in tumor growth by altering the phospholipid composition of the cancer cells’ plasma cells, allowing amplified and mutated growth factor signs to spur tumor growth.

See Also
Meet New Evolving Superbug That Thrives On Sugary Western Diets!

With no LPCAT1, tumors can’t survive. When researchers genetically depleted LPCAT1 in a number of kinds of cancer in mice, such as exceptionally lethal glioblastomas (mind ) and aggressive lung cancer, malignancies shrank dramatically and survival times improved.

The findings demonstrate that LPCAT1 enzyme is a key enzyme that gets dysregulated in cancer, linking common genetic alterations in tumors with changes in their metabolism to drive aggressive tumor growth.

“Advances in DNA sequencing technology have reshaped our comprehension of the molecular basis of cancer, implying a new and more effective method of treating cancer patients,” stated Mischel. “However, to date, precision oncology has to benefit many patients, motivating a deeper search into knowing how genetic alterations in tumors alter the way cancer cells act, and potentially unlocking new techniques to more effectively treat patients.

“These results also imply that LPCAT1 might be a really persuasive new drug target in a wide array of cancer types.”

Download This Notification

Got Questions About this Post?

Ask BioTecNika Experts

Looking for Pharma & Chemistry JobsExam Alerts, Scholarships Alerts, Admissions Alerts, Internships?

Looking for Pharma & Chemistry News, Jobs, Scholarships, Admissions Alerts?

Perfection is her hobby, Reliability is a synonym, Editing is her passion, Excellence is her Goal, Tactfulness is in her genes, Yellow is her Fav color. Preety Suman is the name of the Professional on whom entire BioTecNika relies when it comes to its website.A Gold Medalist in Biotech from SRM University, Chennai with a 9.9 CGPA ( was awarded the Gold Medal by Honorable Prime Minister of India Shri Narendra Modi , as seen in the pic ), She decided to join forces with BioTecNika to ensure India's largest BioSciences Portal expands its reach to every city in India.She has redesigned the new avatar of BioTecNika from scratch and heads the most dynamic, vibrant and well informed Online Team at Biotecnika Info Labs Pvt Ltd